Fish Consumption Linked With Better Survival Outcomes in Colon Cancer

Video

This video examines the results of a prospective study that looked at associations between survival outcomes and fish and omega-3 fatty acid intake among colon cancer patients.

In this video, Erin Van Blarigan, ScD, of the University of California, San Francisco, discusses the results of a prospective study that looked at associations between survival outcomes and fish and long-chain omega-3 fatty acid intake after a colon cancer diagnosis.

The study included 1,011 stage III colon cancer patients who were part of an adjuvant chemotherapy trial, and found that patients who consumed dark meat fish at least twice per month had longer recurrence-free survival (hazard ratio [HR], 0.61; 0.44–0.83; P = .005), disease-free survival (HR, 0.64; 0.48–0.86; P = .007), and overall survival (HR, 0.68; 0.48–0.97; P = .05) compared with those who consumed no fish. The study also found that in patients with COX2 tumor expression, long-chain omega-3 fatty acid was associated with improved disease-free survival.

Results of the study (abstract 585) were presented last month at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content